Europital Opens Oxford Site to Expand Services to UK Biotech

Medical management services provider, Europital, has announced the opening of a new site in Oxford, United Kingdom, in response to demand from small and medium innovators within the biotech industry.

As reported in an Aug. 24, 2020 press release, Europital’s expansion will be targeted toward small and medium biotechs, in particular those that are seeking assistance with the design and execution of first-in-man, Phase I, and Phase II clinical studies. Europital is already working with several UK partners and has forecasted compound annual growth from UK biotech of approximately 30% over the next three years.

“We already partner with several biotechs in the UK and what we have seen is that there is a clear gap in the market for small innovators looking for a science focussed CRO that can provide the detailed knowledge and therapeutic experience,” said Dr. Mohamed El Malt, CEO and chief medical officer of Europital, in the press release. “Gaining access to senior medical CRO expertise can be extremely challenging for the smaller innovators. What they need is a partner to bring a medical department with real-world trial experience to implement study design and protocols and be a scientific driving force behind project’s success.”

The company plans to expand its offering quickly to provide expertise to partners in complex oncology indications, inflammatory diseases, immunology, and infectious diseases studies. Additionally, the new site in Oxford will be used to leverage the company’s Phase III experience with clinical studies that are directly conducted at UK investigative sites.

Source: Europital